Author:
Bestvina Christine M.,Pointer Kelli B.,Karrison Theodore,Al-Hallaq Hania,Hoffman Philip C.,Jelinek Michael J.,Juloori Aditya,Melotek James M.,Murgu Septimiu,Partouche Julien,Vokes Everett E.,Weichselbaum Ralph R.,Pitroda Sean P.,Patel Jyoti D.,Chmura Steven J.
Funder
Bristol-Myers Squibb
University of Chicago
AstraZeneca
Takeda Pharmaceutical Company
University of Chicago Medicine
Bristol-Myers Squibb Foundation
Genentech
Varian Medical Systems
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference24 articles.
1. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review;Arbour;JAMA,2019
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer;Ferrara;Cochrane Database Syst Rev,2020
3. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N Engl J Med,2019
4. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial;Palma;Lancet,2019
5. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study;Gomez;Lancet Oncol,2016
Cited by
63 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献